Kepler Cheuvreux analyst Nicolas Payen upgrades Credit Suisse Group (NYSE:CS) from Hold to Buy.
Investors React Positively To Data From Orphazyme’s Neurodegenerative Disease Candidate
Orphazyme A/S (NASDAQ:ORPH) announced that results from a Phase 2/3 trial of arimoclomol in Niemann-Pick disease type C (NPC) had…